KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Other Non Operating Income (2016 - 2026)

Pacira BioSciences has reported Other Non Operating Income over the past 17 years, most recently at -$135000.0 for Q1 2026.

  • For Q1 2026, Other Non Operating Income fell 103.07% year-over-year to -$135000.0; the TTM value through Mar 2026 reached -$417000.0, down 110.35%, while the annual FY2025 figure was -$6.6 million, 1674.8% down from the prior year.
  • Other Non Operating Income for Q1 2026 was -$135000.0 at Pacira BioSciences, up from -$172000.0 in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $11.4 million in Q4 2022 and troughed at -$16.9 million in Q1 2023.
  • A 5-year average of -$1.6 million and a median of -$165500.0 in 2024 define the central range for Other Non Operating Income.
  • Biggest five-year swings in Other Non Operating Income: skyrocketed 17325.76% in 2022 and later crashed 242.71% in 2023.
  • Year by year, Other Non Operating Income stood at $11.4 million in 2022, then crashed by 242.71% to -$16.2 million in 2023, then soared by 51.37% to -$7.9 million in 2024, then soared by 97.82% to -$172000.0 in 2025, then grew by 21.51% to -$135000.0 in 2026.
  • Business Quant data shows Other Non Operating Income for PCRX at -$135000.0 in Q1 2026, -$172000.0 in Q4 2025, and -$110000.0 in Q3 2025.